welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
Horizon Therapeutics, the maker of TEPEZZA, prepared this document to address questions from the Thyroid Eye Disease (TED) community regarding the short-term disruption in TEPEZZA supply. Horizon is aware of the significant impact TED has on people living with the disease and is working diligently to limit the length of the disruption.
This disruption is the result of recent COVID-19 vaccine production orders required by the government pursuant to the Defense Production Act of 1950 (DPA) related to manufacturing. This has dramatically restricted production capacity at the manufacturing facility that produces TEPEZZA.
Note: If you choose to share or post these FAQs, please share the full document and not select pieces of it, in order to comply with regulatory guidelines.
Questions about TEPEZZA? Talk to Horizon Patient Services.
Call 1-833-469-8331, Mon-Fri, 8 AM – 8 PM EST.
Horizon Patient Services does not provide individual patient care or medical advice.
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis ReductionTop-line results from the OPTIC trial sh...
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 StudyResults from the phase 3 OPTIC study sho...
Early Experience With Teprotumumab for Chronic Thyroid Eye DiseasePurpose: To report the first case of a ...
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseasePrior clinical trials of TEPEZZA(TM) hav...
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 ResultsHorizon Therapeutics plc today announced...
Horizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application...Horizon Therapeutics plc today announced...